Trending...
- $6.4 Million Purchase of Construction Vehicles Plus New Dealership Agreement with Cycle & Carriage for Heavy Equipment Provider to Singapore Region
- A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van
- Klein Civil Rights Expands with New Offices in New York's Historic Woolworth Building
WESTON, Fla., May 28, 2024 ~ Cantex Pharmaceuticals, Inc. has recently announced that their drug, azeliragon, will be featured in four abstracts at the 2024 ASCO Annual Meeting in Chicago. The company, which focuses on developing transformative therapies for cancer and other life-threatening medical conditions, is excited to showcase the progress of their clinical investigations at leading cancer centers.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
- Chicago: Mayor Brandon Johnson Announces New Record Of Nearly 13 Million Shared Bike And Scooter Trips In 2025
- Chicago: Mayor Brandon Johnson Announces Launch Of New Community Reentry Support Center For Women Returning From Incarceration
- Secondesk Launches Powerful AI Tutor That Speaks 20+ Languages
- Automation, innovation in healthcare processes featured at international conference in Atlanta
- Mayor Brandon Johnson Welcomes Vice President Kamala Harris To Chicago For Martin Luther King Jr. Interfaith Breakfast
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
- New Adventure Web Design & Digital Marketing Launches New Website for Village of Valmeyer, IL
- Chicago: Mayor Brandon Johnson and CDPH Commissioner Ige Statement On Trump Cutting Billions In Mental Health And Addiction Services Funding
- UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
- Chicago: Mayor Brandon Johnson convenes CPD And CVI Leaders For Community Safety Roundtable
- Narcissist Apocalypse Marks 7 Years as a Leading Narcissistic Abuse Podcast
- High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
- CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
- YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
- High-End Exterior House Painting in Boulder, Colorado
- Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
- Naperville Police Arrest Two Teens Charged with Sexually Assaulting a Female
- Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Chicago: Mayor Brandon Johnson Statement On Trump Threatening To Halt Federal Funding For Sanctuary Cities
- Chicago: Mayor Brandon Johnson Statement On Trump Revoking Protected Status For Somali Immigrants
- Mayor Brandon Johnson And The Chicago Department Of Business Affairs And Consumer Protection Reaffirm Support For Small Business Community At The Start Of The New Year
- Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
- New Year, New Home: Begin 2026 at Heritage at South Brunswick
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section